Across TCGA pan-cancer cohorts, TSPYL4 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TSPYL4 data layer compared with 29 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher TSPYL4 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TSPYL4 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC and LUAD are the cancer types where TSPYL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	II,III,IV	1.000	0.630	.013	8	view →
LUAD	DFS	Tertile	All	1.000	0.425	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: TSPYL4 tumor-vs-normal RNA expression · all TSPYL4 data types